- CBD or THC? Cannabis Product Labels Often Mislead, Study Finds
- AHA News: Straight Answers to Common Questions About COVID-19 Vaccines
- U.S. Health Agencies Call for Pause in J&J COVID Vaccine After 6 People Develop Clots
- Therapeutic Cancer Vaccine Shows Promise Against Multiple Tumor Types
- Health Highlights: April 13, 2021
- Newborns Won’t Get COVID Through Infected Mom’s Breast Milk: Study
- Physically Active at Work? It’s Not as Healthy as Leisure Exercise
- Americans Are Eating Less Healthily Everywhere, Except at School
- U.K. Variant Won’t Trigger More Severe COVID, Studies Find
- FDA Approves First AI Tool to Boost Colonoscopy Accuracy
Screening Test Approved for Viruses That Cause Blood Cancer

A new screening test to detect Human T-Cell Lymphotropic viruses that cause a rare blood cancer has been approved by the U.S. Food and Drug Administration.
The viruses, abbreviated HTLV-I/II, cause diseases such as adult T-cell leukemia/lymphoma (blood cancer) and myelopathy (inflammation of spinal cord nerves) , the FDA said in a news release. HTLV can be transmitted via breastfeeding, unprotected sex or blood transfusion.
The newly approved test — MP Diagnostics HTLV Blot 2.4 — is meant to supplement existing screening for the viruses, the FDA said. The diagnostic also can differentiate between the two types, HTLV-I or HTLV-II.
Many people infected with HTLV may not be aware of its presence, since the virus does not always trigger symptoms. An infected person can transmit the virus without showing any signs or symptoms, the agency said.
The new test is produced by a Singapore subsidiary of MP Biomedicals, based in Santa Ana, Calif.
More information
Visit the FDA to learn more.
Source: HealthDay